

## Original Research Article

# Frequency of Red cell alloantibodies among pregnant women receiving Antenatal care in a tertiary health facility in Jos, Nigeria

### ABSTRACT

**Aims:**To determine the frequency of red blood cell alloantibodies among pregnant women in Jos, Nigeria.

**Study design:**A cross sectional study was carried out among pregnant women accessing antenatal care.

**Place and Duration of Study:**The study was conducted at Department of Obstetrics and Gynaecology and Department of Haematology and Blood Transfusion, Jos University Teaching Hospital (JUTH) Jos, Nigeria from 24th April 2017 to 31st May 2017.

**Methodology:**We included 200 pregnant women accessing antenatal care. Data on clinical details were obtained with an Interviewer-administered questionnaire. Screening and identification of red blood cell alloantibodies were made using the DiaCells, and DiaPanels (DiaMed GmbH, Switzerland). ABO and Rh blood groups were done using antisera from Biotec (Ipswich, UK).

**Results:**Out of 200 participants, alloantibodies were found in 24 (12.0%) of participants and their specificities were as follows; anti-E, 9 (4.5%); anti- e, 1 (0.5%); anti-C, 6 (3.0%); anti- c, 2 (1.0%); anti- K, 2 (1.0%); anti- P, 1 (0.5%); anti- N, 1 (0.5%), while 2 (1.0%) showed a combination of antibodies of whose specificities could not be determined by the Diamed 11-panel cells. Multigravidity was identified as a risk factor for alloimmunization ( $P= 0.01$ ). However, alloimmunization status was independent of previous abortions, trimester of pregnancy, and ABO blood group of the studied population.

**Conclusion:**Alloantibody screening and identification should be included in routine antenatal care, especially for at-risk populations.

*Keywords: Alloimmunization, antenatal, Jos, Nigeria, Red blood cells, alloantibodies*

### 1. INTRODUCTION

Blood group antibodies are immunoglobulins (Ig) that react with antigens on the surface of red blood cells (RBCs). They can either be acquired naturally or through immunization with foreign RBCs [1]. The naturally occurring antibodies are produced in response to environmental stimulants such as bacteria [1]. These antibodies are present when the corresponding antigens are absent on the red cells [1]. All antibodies to red cell antigens other than naturally occurring anti-A and anti-B are considered 'unexpected' or 'irregular' [2]. They can either be alloantibodies directed toward non-ABO antigens absent on the host's red cells or autoantibodies directed towards self-antigens [2]. Pregnancy and blood transfusion are two major risk factors for developing irregular antibodies (alloimmunization) to RBCs in affected individuals [3]. Other implicated factors include organ transplantation or injection with immunogenic materials [3, 4].

World best practices for prenatal immunohaematologic care of pregnant women include, amongst other things, the screening of unexpected RBCs antibodies in pregnancy [5]. When these antibodies are present, it is necessary to identify and determine their clinical significance [5]. This is important considering its relevance in finding compatible blood when needed and the possibility of haemolytic transfusion reaction and haemolytic disease of the foetus and newborn (HDFN) [6]. In many developing countries of the world, including Nigeria, screening for irregular antibodies and subsequent typing, when present, are not done routinely [6]. Hence the incidence of maternal RBC alloimmunization and its contribution to HDFN and blood transfusion reaction is largely unknown.

Alloimmunization to clinically significant red cell antigens is a major complication associated with blood transfusion services in developing countries [6]. The possibility of developing alloantibodies to red blood cell antigens had been focused on individuals that do not possess Rh D antigen on the surface of their red cells [7]. This led to the use of Rh (D) immunoglobulin (Rhogam), used both as prophylaxis and in therapy, with a resultant significant reduction in cases of severe HDFN and poor obstetric history associated with maternal alloimmunization [8, 9]. However, developing alloimmunization to other red cell antigens has become increasingly problematic, especially the resulting HDFN, and difficulty in provision of compatible blood for transfusion [10]. Neonatal jaundice contributes to 11% of admission and 5.4% of mortality at the special care baby unit (SCBU) at Jos University Teaching Hospital (JUTH) [11]. HDFN is second only to G6PD as a leading cause of neonatal jaundice [11]. Despite the above challenges, data on the prevalence of maternal alloimmunization, and complications including HDFN and transfusion reactions resulting from such alloimmunization is scarce in our environment. With the development and implementation of antenatal Rh (D) immunoglobulin (Rhogam) prophylaxis in Rh D-negative pregnant women in the 1960s, there has been a significant reduction in the frequency of maternal alloimmunization to Rh D antigen, especially in developed countries [12]. However, alloimmunization to Rh D and other clinically significant antigens remains a problem in developing countries, including Nigeria [13]. Alloimmunization to RBC antigens has been implicated in pregnancy losses and poor obstetric history. Also, poorly managed pregnancy losses have resulted in the development of alloimmunization to RBC antigens [14,15]. Timely detection of resulting antibodies in antenatal women will be essential both for transfusion safety in the mother, and early and successful management of haemolytic disease of the foetus and newborn [15]. Alloimmunization in pregnant women has been found to range from 0.4% to 4.8% worldwide [16-21]. This study, therefore, is aimed at investigating the prevalence of alloantibodies in pregnant women in Jos and suggesting routine detection and measures mitigate the consequences in them.

## 2. MATERIAL AND METHODS / EXPERIMENTAL DETAILS / METHODOLOGY

A hospital- based, analytic, cross- sectional study was performed among 200 pregnant women attending Antenatal Clinic of JUTH between April 2017 and May 2017. A sample size of a minimum 70 was calculated using the formula ( $n = (z^2pq)/d^2$ ) [22] for a cross- sectional survey based on a reported prevalence of 4.8% in Port- Harcourt [22,21]. **Two hundred (200)** participants were recruited into the study using nonrandom, convenience sampling. Pregnant women that received any blood components in the preceding 4 months were excluded to prevent false reactions from exogenous antibodies. Furthermore, pregnant women that had received passive immunization with Anti- D IgG or intravenous immunoglobulin in the preceding 3 months were excluded to prevent false negative reactions. Written informed consent was obtained from each study participant. Each participant was interviewed with a pretested, structured, interviewer- administered questionnaire.

ABO blood grouping was done using anti-A, anti-B, and anti-A+B (Biotec, Ipswich, UK), with standard tube agglutination technique. All blood groups were confirmed with known RBCs (serum grouping). Rh grouping was done using anti-D monoclonal reagents (Biotec, Ipswich, UK). The sera were screened alloantibodies using antibody screening panels- 3 cells (Diamed, Switzerland). The serum with alloantibodies was further tested to determine the specificity of the antibodies using an identification panel- 11 cells (Diamed, Switzerland) by tube method in low ionic strength solution and anti- human globulin.

To all the tests that were negative at the AHG phase, was added 1 drop of IgG-sensitized RBCs (Coombs' Control Cells). **This was centrifuged at 1500 rpm for 20 seconds** and examined macroscopically and microscopically for agglutination or haemolysis. The Coombs' Control Cells yielded a positive reaction. If no agglutination was observed, the result for that panel cell was read as invalid, and the test was repeated beginning using that cell.

The data collected were analyzed using Epi Info version 3.4.3. Continuous data are presented as mean and standard deviation (SD). Student's t-test was used to assess the significance between the means of two groups, and ANOVA was used to compare the means of multiple groups. Chi-square was used to compare categorical data. A p-value of <0.05 was considered statistically significant.

## 3. RESULTS AND DISCUSSION

### RESULTS

Within a period of one month, blood samples were collected from two hundred pregnant women receiving antenatal care at Jos University Teaching Hospital.

The ages of the studied population ranged between 18 and 44 years (mean  $\pm$  SD = 29.57  $\pm$  5.99 years). Most (73.5%) of the participants were aged between 20 and 35 years.

The Hausas were the predominant ethnic group accounting for 59 (29.5%) of participants. This was followed by Beroms, 23 (11.5%); Igbos, 14 (7.0%); Ngas, 14 (7.0%); Yorubas, 9 (4.5%); Fulanis, 7 (3.5%); Mwaghavul, 6 (3.0%); Others which included- Afizere, Langtang, Tiv, Idoma, Chibok, Kare- Kare, Efik, Ibibio, Tarok, Kataf, Urhobo, Ibie, Kagoro, Eggon, Ron, Babul, Ikwere, Kono, Mupun, Fem, Igede, Igala, Jukun, Kutere, Irikwe, Bura, Jikun, Amo, Tangali, Igbira, Chip and Jabba ethnic groups accounted for 68 (34.0%).

Most of the participants were civil servants, 58 (29%); followed by housewives, 57 (28.5%). Forty-two (21%) were traders, twenty-seven (13.5%) were students, and sixteen (8.0%) were artisans.

All the participants were married. One hundred and eighteen (59%) had obtained tertiary education, sixty-six (33%) had secondary education, twelve (6%) had primary education, and four (2%) had no formal education (Table 1).

Most of the participants were multigravida, 144 (72.0%), while the remaining fifty-eight (28.0%) were primigravida. Ninety-five (47.5%) were in the third trimester of pregnancy, eighty-four (42.0%) were in the second trimester, and twenty-one (10.5%) were in the first trimester. Fifty-eight (29.0%) of the multigravidae had previous miscarriages, and twenty (10.0%) of them had children with neonatal jaundice. Fourteen (7.0%) of the participants had a previous blood transfusion, two of which had alloantibodies (Table 2).

Alloantibodies were identified in the serum of 24 (12.0%) pregnant women. The specificity of the antibodies were as follows: anti-C, 6 (3.0%); anti- c, 2 (1.0%); anti- K, 2 (1.0%); anti-E, 9 (4.5%); anti- e, 1 (0.5%); anti- P, 1 (0.5%); anti- N, 1 (0.5%), while 2 (1.0%) showed a combination of antibodies of whose specificities could not be determined by the Diamed 11-panel cells (Table 3). Only one (0.5%) of the participants who lacked Rh D antigen on their RBC had an alloantibody in her serum, which was found to be Anti- E.

ABO blood group and Rh type distribution showed 88 (44.0%) were of blood group "O," out of which 84 (42.0%) and 4 (2.0%) were Rh D positive and negative, respectively. Sixty-two (31.0%) of the subjects were of blood group "B," out of which 57 (28.5%) and 5 (2.5%) were Rh positive and negative, respectively. Participants with blood group "A" were 38 (19.0%), of which 35 (17.5%) and 3 (1.5%) were Rh D positive and negative, respectively. The remaining 12 (6.0%) of the participants were of the "AB" blood group, out of which 11 (5.5%) and 1 (0.5%) were Rh D positive and negative, respectively (Table 4).

Association between the obstetric, blood transfusion, previous neonatal jaundice history, ABO/ Rh blood group, and alloimmunization among participants were compared. Seventeen (8.5%) of the multigravida and Seven (3.5%) of the Primigravida had alloantibodies. There was a statistical difference between alloimmunization and number of pregnancy ( $P= 0.01$ ). One (0.5%) of the Rh D negative participant had an alloantibody (anti- E), and the remaining 23 (11.5%) participants lacked Rh D antigens on their red cells. This difference was statistically significant ( $P = 0.003$ ). The distribution of the antibodies was found to be independent of the previous miscarriage, Trimester of pregnancy, and ABO blood group of the participants ( $P = 0.40$ ,  $P= 0.19$ ,  $P= 0.8$  respectively) Table 5.

**Table 1; Socio- demographic characteristics of participants**

| Characteristic    | Frequency (n, %)   |
|-------------------|--------------------|
| <b>Age</b>        |                    |
| ≤20               | 17 (8.5)           |
| 21-25             | 34 (17.0)          |
| 26-30             | 64 (32.0)          |
| 31-35             | 49 (24.5)          |
| 36-40             | 30 (15.0)          |
| 41-45             | 6 (3.0)            |
| <b>Total</b>      | <b>200 (100.0)</b> |
| <b>Ethnicity</b>  |                    |
| <b>Berom</b>      | 23 (11.5)          |
| Fulani            | 7 (3.5)            |
| Hausa             | 59 (29.5)          |
| Igbo              | 14 (7.0)           |
| <b>Mwaghavul</b>  | 6 (3.0)            |
| <b>Ngas</b>       | 14 (7.0)           |
| Yoruba            | 9 (4.5)            |
| Others            | 68 (34.0)          |
| <b>Total</b>      | <b>200 (100.0)</b> |
| <b>Occupation</b> |                    |
| Artisan           | 16 (8.0)           |

|                |                    |
|----------------|--------------------|
| Civil servants | 58 (29.0)          |
| Housewife      | 57 (28.5)          |
| Student        | 27 (13.5)          |
| Trader         | 42 (21.0)          |
| <b>Total</b>   | <b>200 (100.0)</b> |

#### Marital Status

|                |                    |
|----------------|--------------------|
| <b>Married</b> | <b>200 (100.0)</b> |
|----------------|--------------------|

#### Educational Qualification

|                     |                    |
|---------------------|--------------------|
| No formal education | 4 (2.0)            |
| Primary education   | 12 (6.0)           |
| Secondary education | 66 (6.0)           |
| Tertiary education  | 118 (59.0)         |
| <b>Total</b>        | <b>200 (100.0)</b> |

Table 2: Obstetric, neonatal, and previous blood transfusion history of participants

| Characteristics           | Frequency n (%)    |
|---------------------------|--------------------|
| <b>Gravidity</b>          |                    |
| Primigravida              | 56 (28.0)          |
| Multigravida              | 144 (72.0)         |
| <b>Total</b>              | <b>200 (100.0)</b> |
| <b>Trimester</b>          |                    |
| First                     | 21 (10.5)          |
| Second                    | 84 (42.0)          |
| Third                     | 95 (47.5)          |
| <b>Total</b>              | <b>200 (100.0)</b> |
| <b>Miscarriages</b>       |                    |
| None                      | 142 (71.0)         |
| Once                      | 43 (21.5)          |
| Twice                     | 10 (5.0)           |
| Thrice                    | 4 (2.0)            |
| Four times                | 1 (0.5)            |
| <b>Total</b>              | <b>200 (100.0)</b> |
| <b>Blood Transfusions</b> |                    |
| None                      | 186 (93.0)         |
| Once                      | 12 (6.0)           |
| Twice                     | 2 (1.0)            |
| <b>Total</b>              | <b>200 (100.0)</b> |

---

**Neonatal Jaundice**

|                            |             |
|----------------------------|-------------|
| None                       | 180 (90.0)  |
| With hospital admission    | 9 (4.5)     |
| Without hospital admission | 11 (5.5)    |
| Total                      | 200 (100.0) |

---

**Table 3: Frequency and specificity of alloantibodies among participants**

---

| Alloantibody | Frequency n (%) |
|--------------|-----------------|
| anti- E      | 9 (4.5)         |
| anti- C      | 6 (3.0)         |
| anti- K      | 2 (1.0)         |
| anti- c      | 2 (1.0)         |
| anti-e       | 1 (0.5)         |
| anti-P       | 1 (0.5)         |
| anti-N       | 1 (0.5)         |
| Mixed field  | 2 (1.0)         |
| None         | 169 (84.5)      |
| Total        | 200 (100.0)     |

---

*The Mixed field represent alloantibodies (anti - k, - kp<sup>b</sup>, -lu<sup>b</sup>, -xg<sup>a</sup>) of which the specific alloantibody could not be determined by the Diamed 11-panel cells.*

**Table 4: ABO and Rh blood groups of participants**

---

| ABO group | Rh group                     |                              | Total (%) |
|-----------|------------------------------|------------------------------|-----------|
|           | Rh D <sup>positive</sup> (%) | Rh D <sup>negative</sup> (%) |           |
| O         | 84 (42.0)                    | 4 (2.0)                      | 88 (44.0) |
| B         | 57 (28.5)                    | 5 (2.5)                      | 62 (31.0) |

---

|           |            |          |           |
|-----------|------------|----------|-----------|
| A         | 35 (17.5)  | 3 (1.5)  | 38 (19.0) |
| AB        | 11 (5.5)   | 1 (0.5)  | 12 (6.0)  |
| Total (%) | 187 (93.5) | 13 (6.5) | 200 (100) |

**Table 5: Association of risk factors, ABO/ Rh blood group, and alloimmunization among participants**

| Parameter                | Antibody screening |            | Total (%)   | $\chi^2$ | P value | Fisher exact test |
|--------------------------|--------------------|------------|-------------|----------|---------|-------------------|
|                          | Positive           | Negative   |             |          |         |                   |
| <b>Gravidity</b>         |                    |            |             |          |         |                   |
| Multigravida             | 17 (8.5)           | 127 (63.5) | 144 (72.0)  | 0.0184   | 0.0114  |                   |
| Primigravida             | 7 (3.5)            | 49 (24.5)  | 56 (28.0)   |          |         |                   |
| Total                    | 24 (12.0)          | 176(88.0)  | 200 (100.0) |          |         |                   |
| <b>Trimester</b>         |                    |            |             |          |         |                   |
| First                    | 1 (0.5)            | 20(10.0)   | 21 (10.5)   | 0.1875   |         |                   |
| Second                   | 14 (7.0)           | 70 (35.0)  | 84 (42.0)   |          |         |                   |
| Third                    | 9 (4.5)            | 86 (43.0)  | 95 (47.5)   |          |         |                   |
| Total                    | 24 (12.0)          | 176 (88.0) | 200 (100.0) |          |         |                   |
| <b>Miscarriage</b>       |                    |            |             |          |         |                   |
| Previous                 | 7 (3.5)            | 51 (25.5)  | 58 (29.0)   | 4.0464   | 0.3998  |                   |
| None                     | 17 (8.5)           | 125 (62.5) | 142 (71.0)  |          |         |                   |
| Total                    | 24 (12.0)          | 176 (88.0) | 200 (100.0) |          |         |                   |
| <b>Blood transfusion</b> |                    |            |             |          |         |                   |
| Previous                 | 2 (1.0)            | 12 (6.0)   | 14 (7.0)    | 0.0236   | 0.52098 |                   |
| None                     | 22 (11.0)          | 164 (82.0) | 186 (93.0)  |          |         |                   |
| Total                    | 24 (12.0)          | 176 (88.0) | 200 (100.0) |          |         |                   |
| <b>Neonatal jaundice</b> |                    |            |             |          |         |                   |
| Previous                 | 1 (0.5)            | 19 (9.5)   | 20 (10.0)   | 0.04261  | 0.2738  |                   |
| None                     | 23 (11.5)          | 157 (78.5) | 180 (90.0)  |          |         |                   |
| Total                    | 24 (12.0)          | 176 (88.0) | 200 (100.0) |          |         |                   |
| <b>ABO group</b>         |                    |            |             |          |         |                   |
| A                        | 3 (1.5)            | 35 (17.5)  | 38 (19.0)   | 0.8200   |         |                   |
| B                        | 8 (4.0)            | 54 (27.0)  | 62 (31.0)   |          |         |                   |
| AB                       | 2 (1.0)            | 10 (5.0)   | 12 (6.0)    |          |         |                   |
| O                        | 11 (5.5)           | 77 (38.5)  | 88 (44.0)   |          |         |                   |
| Total                    | 24 (12.0)          | 176 (88.0) | 200 (100.0) |          |         |                   |
| <b>Rh group</b>          |                    |            |             |          |         |                   |
| Rh D <sup>positive</sup> | 23 (11.5)          | 164 (82.0) | 187 (93.5)  | 0.0028   | 0.5210  |                   |
| Rh D <sup>negative</sup> | 1 (0.5)            | 12 (6.0)   | 13 (6.5)    |          |         |                   |
| Total                    | 24 (12.0)          | 176 (88.0) | 200 (100.0) |          |         |                   |

## DISCUSSION

Alloimmunization to RBCs antigen results from sensitizing events, majorly previous blood transfusions, pregnancies, and or injection of antigenic substances.

The result showed the frequency of alloantibodies to be 12.0% in the two hundred pregnant women studied. This is comparable to the 13.7% found by Bashawari in a retrospective study of sickle cell anaemia patients in Saudi Arabia [23].

The frequency in this study is less than 16.3% reported in Sokoto by Isaac et al [24]. The high frequency in this study is possibly due to the number of multiparous women (72.0%) involved in the study, as the risk of sensitization is known to increase with pregnancy [25]. Also, most of the women were in their second or third trimester (89.5%) of pregnancy. Hence, there is an increased possibility of detecting alloantibodies that could have been missed if the test had been conducted in the first trimester [26,27]. This could have also resulted from a presumed high phenotypic incompatibility between the mothers and their fetuses. Some of the women with alloantibodies also had previous blood transfusions, which increased the possibility of sensitization. The frequency is higher than 3.4% and 4.8% found among pregnant women in Port Harcourt by Jeremiah et al [19,20]. Also higher than the 4.7% reported in Benin by Adewoyin et al [21]. The difference could be due to the geographical location between Northern and Southern Nigeria, and the sensitivity of the reagents used. This is also far higher than 0.0%, 1.1%, 1.3%, 1.4%, and 1.5% reported in Uttarakhand, Tirupati, New Delhi, Karnataka and Tamil Nadu, respectively [1,12,15,24,28].

Antibodies against antigens of the Rh blood system were the most prevalent (75.0%), followed by antibodies against the Kell blood group antigens (8.3%). Al- Ibrahim et al reported antibodies against Rh and Kell blood group systems accounting for 52.38% and 2.38%, respectively, of the alloantibodies in pregnant women in Saudi Arabia [17]. The anti- E had the highest prevalence of 4.5% in this study comparable to that of Jeremiah et al, where anti-E was found to be the commonest alloantibody with a frequency of 1.2% [20]. This is possibly due to the high prevalence of pregnant women in the environment lacking the E antigens on their red cells. Erhabor et al found that 71.6% of pregnant women in Sokoto North-West Nigeria lacked E antigens on their red cells and were at risk of developing anti- E if exposed to the E antigens [29]. The ability of anti E to cause severe HDFN and HTR is mild compared to those of anti- D and anti- K. This is probably because many anti-E are weak, naturally occurring antibodies [25]. Anti- C was found in 3.0% of the studied population. Jeremiah et al found anti-C to be the most common alloantibody (1.2%) among another group of pregnant women in Port Harcourt [19]. The C antigen is the least immunogenic among the common antigens of the Rh blood group system;  $D > c > E > e > C$  [25]. The corresponding Anti-C can be associated with mild HDFN and HTR [30]. Anti C is very rare in Caucasians, and can be found inseparably with anti- D, where it is more appropriately named anti G [25]. In this study, anti-C was found independent of anti- D similar to the findings in Port Harcourt by Jeremiah et al [19,20]. Anti-K and anti-c each had a prevalence of 1.0% in this study. Jeremiah et al reported an anti-K prevalence of 0.8% and 1.0% in two different studies among pregnant women in Port Harcourt [19,20]. K antigen stimulates the formation of anti-K in about 10% of K-negative people given one unit of K-positive blood [25]. About 0.1% of all cases of HDFN are caused by anti- K; most of the mothers will have had previous blood transfusions [25]. None of the participants in this study with K alloantibodies had previous blood transfusions. Anti-c is the most immunogenic after anti-D in the Rh group system [25]. Anti-e, anti-N and anti-P accounted for 0.5% each of the alloantibodies found in this study. Anti-N is rare and nearly always cold-reactive IgM [25]. Anti-P1 is naturally occurring and commonly found in the serum of P1-negative individuals. Anti-P1 rarely causes transfusion reactions because it is usually not reactive above 30°C [25]. The low prevalence of anti-c and anti-e is in keeping with studies that reported high prevalence of the c and e antigens in Nigeria. Erhabor et al in Sokoto reported the prevalence of Rh c and e phenotypes at 92% and 98.5% while Jeremiah et al in Port Harcourt reported a prevalence of 99.8% and 98.7% respectively [31,32]. No anti- D was detected despite 6.5% of the studied subjects being Rh D negative similar to the findings by Jeremiah et al [19,20] and was slightly higher than 4.7% reported by Adewoyin et al [21]. Only one (7.7%) of the thirteen Rh D negative participants had an alloantibody (anti- E) in her serum. The participant's husband was said to be Rh D negative, and so was not expected to have anti-D in her serum. In Sokoto and Benin, Isaac et al and Adewoyin et al respectively, also reported alloantibody in one of the Rh D negative participants [21,24]. The specificity of this antibody was not determined in the findings by Isaac et al [23]. Adewoyin et al found reported the antibody to be anti- D in a multi gravid participant who had previously received Rhogam [21]. This is at variance with the studies in Port Harcourt, where no alloantibodies were found in the studied Rh D negative populations [19,20]. ABO incompatibility between foetus and mother, use of Rhogam and improved health-seeking behaviour and better blood transfusion practice are possible explanations for these findings. Also, only 17% of D negative women are reported to become immunized by one pregnancy with an Rh D-positive offspring [25]. This differs markedly from the study in Tirupati, where Suresh et al reported an anti- D prevalence of 63.8% among Rh D-negative participants in a study population with 6.5% being Rh D-negative [1]. Alloantibodies in this study were more common in participants who had more than one pregnancy and those with Rh D antigens on their red blood cells. These differences were statistically significant ( $P= 0.01$ ). This is at variance from the findings by Adewoyin et al, where alloantibodies were commoner (71%) among primigravida or those pregnant for the second time [21].

Regular screening for maternal alloantibodies is not common in practice around this setting, either for the prevention of HDFN or for blood transfusion practice. Fortunately, the need for management of anti- D negative women who have developed alloimmunisation endangering their fetuses is not common as improved health care and use of Rhogam prophylactically has reduced such incidences. This may not be true for women that are not accessing health care in a tertiary institution. Also, there is the danger in future of finding compatible blood donors for women that have developed alloantibodies. The slightly higher alloantibodies among previously transfused participants suggest the need for putting up Institutional protocol and national policies detection, prevention and management of maternal alloimmunization by relevant stakeholders.

## 4. CONCLUSION

This study showed that alloantibodies is produced in pregnant women and majorly directed against antigens of the Rh blood group system, particularly in multigravidae women. Therefore, there is a need to expand the battery of tests done during antenatal care to include, among others, antibody screening, especially when such women are multigravida, had previous abortions and or had a previous blood transfusion, and those needing a blood transfusion. Postnatal prophylactic use of Rhogam among Rh D negative women is advocated and should be made a national policy with some subsidy to make it readily available nationwide.

## CONSENT

All authors declare that 'written informed consent was obtained from the participants for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editorial office/Chief Editor/Editorial Board members of this journal.'

## ETHICAL APPROVAL

Ethical approval (ref; JUTH/DCS/ADM/127/XIX/6587) was obtained from JUTH Research and Ethics Committee before the commencement of the study.

## REFERENCES

1. Suresh B, Sreedhar BKV, Arun R, Jothibai DS, Bharathi T. Prevalence of "unexpected antibodies" in the antenatal women attending the Government Maternity Hospital, Tirupati. *Journal of Clinical and Scientific Research*. 2015; 4: 22-30.
2. Giblet ER. Blood group alloantibodies: An assessment of some laboratory practice. *Transfusion*. 1997; 17: 29-308.
3. Prinzena L, Staalb HM, Rouwettea SJM, Beckersc EAM, ten Broekeb RHM, van Rhijnb LW et al. Triple Red Blood Cell Alloantibody Formation After Bone-Allograft Transplantation. *American Journal of Transplantation*. 2013; 13: 229- 231.
4. Lappen JR, Stark S, Gibson KS, Prasad M, Bailit JL. Intravenous drug use is associated with alloimmunization in pregnancy. *American Journal of Obstetrics and Gynecology*. 2016; 214: 399- 400.
5. British Committee for Standards in Haematology. Guidelines for blood grouping and red cell antibody testing during pregnancy. Jul 2008. [www.bcshguidelines.org](http://www.bcshguidelines.org).
6. Adias TC, Erhabor O. Suboptimal testing for alloantibodies in sub-Saharan Africa: Bane to effective Immunohaematological services delivery. *International Journal of Medical Sciences and Health Care*. 2013; 1: 13- 22.
7. Santavy J. Haemolytic disease in the newborn - history and prevention in the world and the Czech Republic. *Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia*. 2010; 154: 147– 151.
8. Liunbruno GM, D'Alessandro A, Rea F, Piccinini V, Catalano L, Calizzani G, et al. The role of antenatal immunoprophylaxis in the prevention of maternal - foetal anti- Rh(D) alloimmunization. *Blood Transfusion*. 2010; 8: 8–16.
9. Velati C. A survey of the current use of anti-D immunoprophylaxis and the incidence of haemolytic disease of the newborn in Italy. *Blood Transfusion*. 2007; 5: 7–14.
10. Moise KJJ. Non-anti-D antibodies in red-cell alloimmunization. *European Journal Obstetrics & Gynecology and Reproductive Biology*. 2000; 92: 75 –81.
11. Toma BO, Ige OO, Abok II, Onwuanaku C, Abah RO, Donli A. Pattern of neonatal admissions and outcome in a tertiary institution in north central Nigeria. *Journal of Medicine in the Tropics*. 2013; 15: 121 - 125.
12. Varghese J, Chacko MP, Rajaiiah M, Daniel D. Red cell alloimmunization among antenatal women attending a tertiary care hospital in south India. *Indian Journal of Medical Research*. 2013; 138: 68–71.
13. Erhabor O, Isaac Z, Yakubu A, Adias TC. Abortion, ectopic pregnancy and miscarriages in Sub Saharan Africa: Challenges of Rhesus isoimmunisation in Rhesus negative women. *Open Journal of Obstetrics and Gynaecology*. 2013; 3: 15-26.
14. Patel J, Shukla R, Gupte S. Red Cell Alloimmunization in Multitransfused Patients and Multiparous Women. *Indian Journal of Hematology and Blood Transfusion*. 2009; 25: 49-52.
15. Pahuja S, Gupta SK, Pujani M, Jain M. The prevalence of irregular erythrocyte antibodies among antenatal women in Delhi. *Blood Transfusion*. 2011; 9: 388-93.
16. Koelewijn JM, Vrijkotte TG, van der Schoot CE, Bonsel GJ, de Haas M. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. *Transfusion*. 2008; 48: 941- 952.

17. Al-Ibrahim NA, Al Saeed AH. Red blood cell alloimmunisation among Saudi pregnant women in the central province of Saudi Arabia. *Kuwait Medical Journal*. 2008; 40: 116- 123.
18. Gottvall T, Filbey D. Alloimmunization in pregnancy during the years 1992-2005 in the central west region of Sweden. *ActaObstetriciaetGynecologicaScandinavica*. 2008; 87: 843- 848.
19. Jeremiah ZA, Mordi A, Buseri FI, Adias TC. Frequencies of maternal red blood cell alloantibodies in Port Harcourt. Nigeria *Asian Journal of Transfusion Science*. 2011; 5: 39- 41.
20. Jeremiah ZA, Mordi A. Evaluation of the clinical utility of maternal alloantibody screening as a surrogate to antiglobulin cross matches procedures in resource-limited settings. *International Journal of Blood Transfusion and Immunohematology*. 2011; 1: 1 -6.
21. Adewoyin AS, Adeyemi O, Ande AB, Awodu OA. Immune erythrocyte alloantibodies among pregnant women attending an antenatal clinic in a tertiary health facility, Benin City, Nigeria. *J ApplHematol* 2023; 14: 1-6.
22. Araoye MO. Sample size determination. In: Araoye MO ed. *Research Methodology with Statistics for Health and Social Sciences: Nathadox, Ilorin* 2004; 115–122.
23. Bashawari LAM. Red cell alloimmunization in sickle cell anaemia. *Eastern Mediterranean Health Journal*. 2007; 13: 5.
24. Isaac IZ, John RT, Imoru M, Udomah FP, Erhabor O, Ango IG et al. Effect of Previous Stillbirth on the Formation of Alloantibody among Women in Sokoto Tertiary Hospital. *Asian Journal of Medicine and Health*. 2016; 1: 1- 8.
25. Daniels G, Contreras M, Allard S. Red cell Immunohaematology. In: Hoffbrand VA, Higgs RD, Keeling MD, Mehta AB (eds). *Postgraduate Haematology*. 7th edition. Wiley- Blackwell, London 2016; 195- 213.
26. Gajjar, K, Spencer C. Diagnosis and management of non-anti-D red cell antibodies in pregnancy. *The Obstetrician &Gynaecologist*. 2009; 11: 89- 95.
27. Thompson S, Eggington J, Dodd A, Qureshi R, Turner E. Late developing red cell antibodies in pregnancy. *Transfusion Medicine*. 2003; 13: 8- 9.
28. Thakur B, Kaushik S, Kishore S, Kumar R, Rajput A. 2016. ABO/Rh distribution pattern and prevalence of irregular antibodies in healthy blood donors of Uttarakhand. *Journal of Evolution of Medical and Dental Sciences*. 2016; 5: 3852-3856.
29. Devi SA, Alwar VA, Sitalakshmi S, Ramesh Kumar K, Mhaskar R. Red blood cell antibody screening in pregnancy. *Asian Journal of Transfusion Science* 2011; 5: 56.
30. Webert KE, Smith JW, Arnold DM, Chan HHW, Hedde NM, Kelton JG. *Transfusion Medicine; Red Cell, Platelet, and White Cell Antigens*. In: Greer JP, Arber DA, Glader B, List AF, Means RT (eds). *Wintrobe's Clinical Hematology*. 13th edition. Lippincott Williams & Wilkins, Philadelphia 2014; 1193- 1273.
31. Erhabor O, Kabiru SA, Abdulrahman Y, Okwesili A, Onuigwe F, Isaac ZI. Rh (E) phenotype among pregnant women in Sokoto, North Western Nigeria. *American Journal of PharmTech Research*. 2014; 4: 84- 92.
32. Erhabor O, Okwesili A, Aliyu BS, Onuigwe F, Buhari H, Bagudo A et al. Prevalence of Rhesus c And e Phenotype Among Pregnant Women Attending Antenatal Clinic In UsmanuDanfodiyo University Teaching Hospital, Sokoto. *Journal of Gynecology &.Neonatal Biology*. 2016; 2: 13-16.

## **DEFINITIONS, ACRONYMS, ABBREVIATIONS**

Here is the Definitions section. This is an optional section.

**Term:** Definition for the term